Stephen V Liu, MD· @StephenVLiu · X·· 4 小时前评分70
正文 · 原文
#ESMO26 Dr. Chongrui Xu presents phase III HERON-Lung01 trial: ruzaltatug rezetecan (HER3 ADC) vs platinum chemo in EGFR NSCLC post TKI. ADC superior: PFS 8.3 vs 5.4m, HR 0.47 with OS trend (HR 0.70, ns) despite crossover. RR 60% vs 34% Low rates of discontinuation, ILD rate 2.4% and most toxicity hematologic. #ESMOAmbassadors
93 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Stephen V Liu, MD · x.com